Akebia Therapeutics (AKBA) Cash from Operations Growth (3y) (2016 - 2026)
Akebia Therapeutics (AKBA) Cash from Operations Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 8.25% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 52.97% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 5.90% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 43.42% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -10.08% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -8.76% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 65.60% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Akebia Therapeutics | 244.72 Mn | 89.17 Mn | 38.70 Mn | -0.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.96% |
| Mar 31, 2026 | -6.54% |
| Dec 31, 2025 | 36.96% |
| Sep 30, 2025 | -5.97% |
| Jun 30, 2025 | 39.74% |
| Mar 31, 2025 | 14.34% |
| Dec 31, 2024 | 58.57% |
| Sep 30, 2024 | 50.82% |
| Jun 30, 2024 | 45.78% |
| Mar 31, 2024 | 35.00% |
| Dec 31, 2023 | 57.83% |
| Sep 30, 2023 | 35.92% |
| Jun 30, 2023 | -53.97% |
| Mar 31, 2023 | 41.94% |
| Dec 31, 2022 | 15.96% |
| Sep 30, 2022 | 45.44% |
| Jun 30, 2022 | 7.20% |
| Mar 31, 2022 | 46.08% |
| Dec 31, 2021 | 5.19% |
| Sep 30, 2021 | -65.29% |